Urol. praxi. 2019;20(3):112-115 | DOI: 10.36290/uro.2019.058

Immunotherapy in the treatment of urological malignancies

MUDr. Jana Katolická, Ph.D.1, MUDr. Petr Filipenský, Ph.D.2
1 Onkologicko-chirurgické oddělení, FN u svaté Anny, Brno
2 Urologické oddělení, FN u svaté Anny, Brno

The efficacy of novel immunotherapeutics, particularly checkpoint inhibitors, hold promise for a wide variety of tumor types in
uro-oncology. This development is perhaps best illustrated by the current treatment for patients with metastatic renal cell carcinoma
and urothelial cancer. Further development of biomarkers for predicting therapeutical response is required to achieve
optimal efficacy with these therapeutic interventions.

Keywords: immunotherapy, renal cell cancer, prostate cancer, urothelial cancer

Published: July 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J, Filipenský P. Immunotherapy in the treatment of urological malignancies. Urol. praxi. 2019;20(3):112-115. doi: 10.36290/uro.2019.058.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bartůňková J, Podrazil M, Špíšek R. Imunoterapie v léčbě nádorových onemocnění. Remedia 2015; 25: 34-38.
    2. List T, Neri D. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol 2013; 5(Suppl. 1): 29-45. Go to original source... Go to PubMed...
    3. Heinzer H, Huland E. Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J Urol 2001; 19: 111-119. Go to original source... Go to PubMed...
    4. Motzer RJ, Escudier B, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373: 1803-1813. Go to original source... Go to PubMed...
    5. Motzer RJ, Tannir NM, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018; 378: 1277-1290. Go to original source... Go to PubMed...
    6. Damber JE, Aus G. Prostate cancer. Lancet 2008; 371: 1710-1721. Go to original source... Go to PubMed...
    7. Rodrigues DN, Rescigno P, Liu D, et al. Immunogenomic analyses associated immunological alterations. J Clin Invest 2018; 128(10): 4441-4453. Go to original source...
    8. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115: 3670-3679. Go to original source... Go to PubMed...
    9. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422. Go to original source... Go to PubMed...
    10. Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer vs docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) Proc Am Soc Clin Oncol (2009 Genitourinary Cancer Symposium); Abstract # LBA150.
    11. Cell Genesys, Inc. Cell Genesys Completes Patient Recruitment for First Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer. [2009-02-01]. Dostupné z: http://phx.corporate-ir.net/phoenix.zhtml?c_98399&p_irolnewsArticle&ID_1024159&highlight
    12. Becker JT, McNeel DG. Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination. J Immunother Cancer. 2013; 1: 2. Go to original source... Go to PubMed...
    13. DiPaola RS, Chen YH, Bubley GJ, et al. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol. 2015 Sep; 68(3): 365-371. Go to original source... Go to PubMed...
    14. Pili R, Haggman M, Stadler W, Gingrich J, Assikis V, Björk A, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; 29: 1-10. Go to original source... Go to PubMed...
    15. Sternberg C, Armstrong A, et al. Randomized, double-blind, placebo-controlled study of tasquinimod in men with metastatic castrate-resistant prostate cancer. J Clin Oncol 34: 2636-2643.
    16. Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients With metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017; 35: 40 Go to original source... Go to PubMed...
    17. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2014; 15: 700-712. Go to original source... Go to PubMed...
    18. Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med. 2017; 377: 1409-1412. Go to original source... Go to PubMed...
    19. Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti - PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016; 7: 52810-52817. Go to original source... Go to PubMed...
    20. www.ema.europa.eu
    21. www.sukl.cz
    22. Sharma P, Retz M, Siefker-Radtke A, Baron A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet 2017; 18: 312-322. Go to original source... Go to PubMed...
    23. Rosenberg JE, Censits JH, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinumbased chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387: 1909-1920. Go to original source... Go to PubMed...
    24. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389(10064): 67-76. Go to original source... Go to PubMed...
    25. Powels T, Durán I, et al. A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]. Lancet 2018; 391(10122): 748-757. Go to original source...
    26. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med, 2017; 376(11): 1015-1026. Go to original source... Go to PubMed...
    27. Balar A, Bellmunt J, O'Donnell P, et al. Pembrolizumab (pembro) as frst-line therapy for advanced/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study. Annals of Oncology. 2016; 27(6): 1-36. Go to original source...
    28. Santoni M, Massari F, Di Nunno V, et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018; 7: 212528. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.